Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

Group 1 - The core stock price of Ruimait rose by 2.02% to 84.97 CNY per share, with a total market capitalization of 7.613 billion CNY as of January 23 [1] - The company experienced a net inflow of main funds amounting to 4.8854 million CNY, with large orders accounting for 20.08% of total purchases [1] - Year-to-date, Ruimait's stock price has decreased by 0.86%, with a 5-day decline of 5.84% and a 20-day increase of 2.99% [2] Group 2 - Ruimait, established on July 27, 2001, specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, focusing on conditions like obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - The company's revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] - As of September 30, 2025, Ruimait reported a revenue of 808 million CNY, reflecting a year-on-year growth of 34.24%, and a net profit of 180 million CNY, with a growth of 43.87% [3] Group 3 - Ruimait has distributed a total of 228 million CNY in dividends since its A-share listing [4] - As of September 30, 2025, the number of shareholders increased by 16.36% to 7,971, while the average circulating shares per person decreased by 14.20% to 7,080 shares [3] - Among the top ten circulating shareholders, Huatai-PineBridge Healthcare Mixed Fund is the sixth largest, holding 1.2953 million shares as a new shareholder [4]

Core Insights - China's foreign trade is accelerating its upgrade from "quantity stability" to "quality improvement," driven by cross-border e-commerce and port openness, with Wuxi emerging as a significant player in this transformation [1] Group 1: Trade Performance - Wuxi's total import and export value for 2025 surpassed 800 billion yuan, reaching 829.28 billion yuan, a year-on-year increase of 7.6% [1] - The number of enterprises engaged in import and export in Wuxi exceeded 14,000, an increase of over 3,500 compared to the end of the 13th Five-Year Plan [1] Group 2: Technological Innovation - The "AI digital content production assembly line" at Wuxi's Daliyu Live Streaming Base enables local companies to quickly generate bilingual advertising videos, facilitating access to overseas markets [1][2] - The base's digital tools have successfully helped local businesses, such as a pickleball racket company, to sell products to Africa [2] Group 3: Logistics and Transportation - Wuxi Shuofang Airport's international cargo transport volume reached 34,000 tons in 2025, with e-commerce cargo volume doubling compared to 2024 [3] - The airport has increased its direct flights to Latin America, with the Wuxi-Mexico City route expanding from three to five flights per week due to rising demand [3][4] Group 4: Economic Activation - The integration of manufacturing, e-commerce, and logistics in Wuxi is revitalizing the economy, showcasing a successful model of "industrial base + digital channels + hub infrastructure" [5] - The opening of the Wuxi-Mexico City route directly supports businesses in capturing market opportunities in Latin America, transforming manufacturing capacity into global delivery advantages [5] Group 5: Policy Support - The "2025 Wuxi Cross-Border Trade Facilitation Action Plan" outlines strategies to enhance port facilities, expand international logistics channels, and improve the digitalization of cross-border trade [6] - The plan includes innovative measures for customs and logistics collaboration, such as 24/7 appointment customs clearance and integrated supervision of various cargo types [6]

Financial Data and Key Metrics Changes - Revenue grew 21% year over year to $10.1 billion, with operating margins at 37% reflecting investments in R&D and manufacturing scale [8][16][29] - Proforma EPS increased 22%, marking the third consecutive year of growth above 20% [16] - Free cash flow rose to $2.5 billion, up from $1.3 billion in 2024 [16] Business Line Data and Key Metrics Changes - Total procedures grew 19%, with da Vinci procedures increasing 17% and Ion procedures growing 51% [5][16] - Single-port procedures grew 87%, while multi-port procedures increased 17% [5][11] - In Q4, da Vinci procedures in the U.S. increased 15% to over 2 million, while international procedures grew 23% [6][19] Market Data and Key Metrics Changes - U.S. procedures increased 16%, with da Vinci procedures growing 15% and Ion procedures growing 41% [17] - Internationally, da Vinci procedures grew 21%, with notable growth in Canada, India, Korea, and various European markets [20][21] - Japan's procedure growth was lower than expected due to capital placement challenges, with potential reimbursement changes anticipated in 2026 [21] Company Strategy and Development Direction - The company focuses on four strategic priorities: launching da Vinci 5, increasing adoption of focused procedures, building industrial scale, and enhancing digital tools [4][13] - Plans to expand into ambulatory surgery centers (ASCs) and enhance training and support for customers [19][56] - Continued investment in market access activities and local evidence generation to meet clinical and economic objectives [6][7] Management's Comments on Operating Environment and Future Outlook - Management believes the company is in the early stages of advancing minimally invasive care, with significant growth opportunities ahead [4][78] - Anticipated da Vinci procedure growth for 2026 is projected between 13%-15%, driven by general surgery and international procedures [36] - Expected gross profit margin for 2026 is projected to be between 67% and 68% of net revenue, with various factors impacting this guidance [37] Other Important Information - The company placed 1,721 da Vinci systems in 2025, including 870 da Vinci 5 systems [7][23] - The installed base of da Vinci systems increased by 12% to over 11,100 systems, with average system utilization rising by 4% [17][26] - The company plans to introduce additional products and features for da Vinci 5 in 2026 [10] Q&A Session Summary Question: FDA approvals for cardiac non-force feedback instruments - Management discussed the importance of supporting cardiac surgery and the foundational work being done, including training pathways and developing cardiac-specific instrumentation [41][42][44] Question: Advanced imaging features in the robotic ecosystem - Management explained that advanced imaging capabilities are being developed, which will add revenue streams and improve surgical outcomes [48][49] Question: ASC opportunity and key procedures - Management highlighted the growing ASC opportunity, focusing on high-quality clinical outcomes and the need for repeatable procedures [53][55] Question: Gross margin and operating expenses assumptions - Management provided insights into the dynamics affecting gross margin, including higher trade-ins and the mix of da Vinci 5 systems [64][66] Question: Competition in China - Management acknowledged increased competition in China but expressed confidence in their ability to compete effectively with local robotic companies [68][70]

Financial Data and Key Metrics Changes - Revenue grew 21% year over year to $10.1 billion, with operating margins at 37% reflecting investments in R&D and manufacturing scale [7][15][27] - Proforma EPS increased 22%, marking the third consecutive year of growth above 20% [15] - Free cash flow rose to $2.5 billion from $1.3 billion in 2024, driven by increased profitability and lower capital expenditures [15] Business Line Data and Key Metrics Changes - Total procedures grew 19%, with da Vinci procedures increasing 17% and Ion procedures growing 51% [5][14] - In Q4, da Vinci procedures grew 18%, with general surgery in the U.S. and broad-based growth in international markets driving this increase [15][17] - The installed base of da Vinci systems increased by 12% to over 11,100 systems, while average system utilization rose by 4% [16] Market Data and Key Metrics Changes - U.S. da Vinci procedures increased 15% to over 2 million, while international procedures grew by 23% to over 1.1 million [5][19] - Growth rates were 21% in Europe, 24% in Asia, and 27% in the rest of the world [5] - In Q4, total procedures outside the U.S. grew 22%, with notable increases in Canada, India, Korea, and distributor markets [19] Company Strategy and Development Direction - The company focuses on four strategic priorities: launching da Vinci 5, increasing adoption of focused procedures, building industrial scale and product quality, and enhancing digital tools [4][5] - Plans to expand the da Vinci XIR system and related economic programs to increase access to da Vinci surgery internationally and in U.S. ambulatory surgery centers [7][11] - Continued investment in market access activities and local evidence generation to meet clinical and economic objectives [6] Management's Comments on Operating Environment and Future Outlook - Management believes the company is in the early stages of advancing minimally invasive care, with significant long-term opportunities ahead [4][5] - Anticipated full-year da Vinci procedure growth for 2026 is projected to be between 13%-15%, driven by general surgery in the U.S. and international procedures [32] - The company expects gross profit margins to be within a range of 67%-68% of net revenue for 2026, with potential impacts from tariffs and product mix [33] Other Important Information - The company received FDA clearance for several cardiac procedures on da Vinci 5, with plans for a measured rollout to support training and adoption [8][36] - The My Intuitive Plus digital subscription package is expected to enhance customer engagement and provide additional revenue streams starting in 2026 [55] Q&A Session Summary Question: About FDA approvals for cardiac non-force feedback instruments - Management discussed ongoing support for cardiac surgery and the importance of training pathways and developing specific instrumentation for cardiac procedures [36][37] Question: Expanding footprint in ASCs - Management highlighted the growing opportunity in ASCs for lower acuity procedures and the need for high-quality clinical outcomes and operational infrastructure [41][42] Question: Gross margin and operating expenses assumptions - Management explained the dynamics affecting gross margin, including higher trade-ins and the mix of da Vinci 5 systems, while also addressing operating expense growth expectations [46][47] Question: Position in China and competition - Management acknowledged increased competition in China but expressed confidence in their ability to compete effectively with local robotic companies [49][50]

证券之星消息，截至2026年1月22日收盘，艾隆科技(688329)报收于24.51元，下跌0.61%，换手率 1.72%，成交量1.33万手，成交额3250.23万元。 1月22日的资金流向数据方面，主力资金净流出257.95万元，占总成交额7.94%，游资资金净流入32.53 万元，占总成交额1.0%，散户资金净流入225.42万元，占总成交额6.94%。 近5日资金流向一览见下表： 艾隆科技2025年三季报显示，前三季度公司主营收入2.8亿元，同比上升25.12%；归母净利润-95.89万 元，同比上升96.56%；扣非净利润-1146.72万元，同比上升66.35%；其中2025年第三季度，公司单季度 主营收入1.49亿元，同比上升83.53%；单季度归母净利润743.13万元，同比上升182.09%；单季度扣非 净利润662.45万元，同比上升160.26%；负债率42.74%，投资收益-424.88万元，财务费用468.61万元， 毛利率45.79%。艾隆科技（688329）主营业务：公司专注于医疗物资的智能管理领域,通过打造医疗物 资智能管理设备及软件信息平台,为各级医疗服务机构提供医疗物资智能 ...

【中泰研究丨晨会聚焦】医药祝嘉琦：政策打通手术机器人收费 瓶颈，临床应用有望加速落地 证券研究报告/晨会聚焦 2026 年 01 月 22 日 分析师：戴志锋 执业证书编号：S0740517030004 Email：daizf@zts.com.cn 欢迎关注中泰研究所订阅号 晨报内容回顾 1、《【中泰研究丨晨会聚焦】地产 由子沛：美国次贷危机下的房地产市 场》2026-01-20 2、《【中泰研究丨晨会聚焦】固收 吕品：商品行情"缩圈"，关注债市 长端品种走势分化》2026-01-19 3、《【中泰研究丨晨会聚焦】固收 林莎：从星辰到算力，春季躁动基础 仍在？》2026-01-18 【医药】祝嘉琦：政策打通手术机器人收费瓶颈，临床应用有望加速落地 事件：近日，国家医保局正式发布《手术和治疗辅助操作类医疗服务价格项目立项指南（试行）》， 聚焦医疗技术前沿成果，围绕 3D 打印、示踪增强成像、能量器械、术中影像引导、机械臂与远程 手术等医疗科技创新成果，进行统一价格立项，规范形成 37 项价格项目、5 项加收项、1 项扩展 项。 分类规范机械臂辅助操作价格项目，聚焦临床价值进行差异化收费。立项指南聚焦手术机器人在 ...

Group 1 - The three major indices experienced fluctuations and turned negative, with the pharmaceutical and biotechnology sectors declining. The medical device sector saw a slight drop, with the CSI Medical Devices and Services Index falling by 0.34%. Notable gainers included Yingke Medical, which rose over 3%, and Hualan Shares and Guanhao Biological, which also had significant increases [1] - The Medical Device ETF (159873) recorded a half-day trading volume of nearly 9 million yuan, leading among similar products, with a turnover rate exceeding 3%. Over the past 10 days, the ETF has seen a cumulative net inflow of 119 million yuan, bringing its latest scale to 236 million yuan, making it the largest in its category [1] - The Medical Device ETF closely tracks the CSI Medical Devices and Services Index, which selects listed companies corresponding to the healthcare theme from the CSI All Share Index to reflect the overall performance of these companies [1] Group 2 - The Innovation Drug ETF Tianhong (517380) has also seen continuous net inflows, accumulating 426 million yuan over the past 12 days. It is the only ETF in the market tracking the Hang Seng Hong Kong-Shenzhen Innovation Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization [2] - According to industry insiders, multiple public fund institutions have applied for medical and healthcare-themed funds this year. It is anticipated that the pharmaceutical industry will gradually recover from its bottom by 2026, with overall revenue growth stabilizing. Key focus areas will include the innovative drug industry chain, CXO (Contract Research Organization) sector, and innovative medical consumables [2] - CITIC Securities highlighted the significance of innovation, noting that Chinese pharmaceuticals possess advantages in "innovation upgrades and supply chain resilience." By 2025, the upfront payments for overseas licensing of innovative drugs are expected to significantly exceed the total for the previous year, with medical devices also exploring international markets [2]

Summary of China Healthcare Industry Conference Call Industry Overview - **Industry**: China Healthcare Industry - **Report Date**: January 21, 2026 - **Sentiment**: Cautiously optimistic outlook for 2026 regarding hospital capital expenditures and market dynamics [1][2] Key Insights Capital Expenditure Trends - **Stable to Moderate Growth**: Hospital capital expenditures are expected to remain stable with moderate growth in 2026 [2] - **Survey Results**: 59% of surveyed hospital managers anticipate capital expenditure growth in 2026, up from 43% in late 2024, but still below 85% in late 2023 [3] - **Projected Growth Rate**: Expected capital expenditure growth of 4.7% in 2026, compared to 3.0% growth anticipated for 2025 [3] - **Actual Growth Expectations**: Respondents expect actual capital expenditure growth of 5.8% for 2025, indicating limited visibility on actual demand [3] Key Drivers of Expenditure - **Primary Drivers**: 1. Hospital Surplus (69%) 2. Patient Demand (50%) 3. Local Fiscal Budgets (44%) [3] - **Service Volume Constraints**: Factors such as Diagnosis-Related Group (DRG) payment limits and medical insurance settlements are seen as major constraints on service volume [3] Equipment and Technology Focus - **Investment Priorities**: Hospitals are prioritizing investments in AI, endoscopy, and imaging equipment, with a focus on surgical and flexible endoscopes, followed by CT and ultrasound [3] - **Weak Demand**: In vitro diagnostics are expected to remain weak [3] Company-Specific Insights Beneficiaries of Capital Expenditure Growth - **Mindray Medical (300760.SZ)**: Expected to benefit from a stable capital expenditure environment, with anticipated single-digit revenue growth in 2026. The company is expected to maintain a 16% share of planned capital expenditures [4][10] - **United Imaging (688271.SS)**: Anticipated to benefit from strong demand in high-end imaging, with projected revenue growth of approximately 21% in 2026 [4][11] - **New Industries (300832.SZ)**: Expected to face continued pricing pressure in in vitro diagnostics but may achieve above-industry growth due to healthy demand for chemical luminescence analyzers [4][12] - **Huatai Medical (688617.SS)**: Positioned to capitalize on the growing adoption of pulse field ablation technology, with projected revenue growth of 30% in 2026 [4][13] - **Guichuang Tongqiao (2190.HK)**: Expected to see revenue growth of around 30% driven by increased demand for neurointerventional and peripheral interventional procedures [4][15] Challenges for Global Players - **GE Healthcare**: Faces mixed impacts from increased capital expenditure and growing preference for local brands, which may offset some growth [4][16] - **Siemens Healthineers (SHL)**: Cautious outlook due to slow recovery in utilization rates and increased pricing pressure from procurement policies [4][17] - **Philips (PHIA)**: Similar cautious outlook with potential declines in market share for CT and ultrasound equipment [4][18] - **Olympus (7733.T)**: Expected to face challenges in maintaining market share in the digestive endoscopy market [4][19] - **Hologic (6869.T)**: Anticipated slowdown in clinical testing volumes and potential market share decline in hematology [4][20] Additional Observations - **Market Dynamics**: The report highlights a complex landscape for global medical technology companies in China, with both opportunities and pressures from local competition and procurement policies [4][16][17][18][19][20] - **Emerging Trends**: The shift towards local brands and the impact of procurement policies are significant trends that may reshape the competitive landscape in the healthcare sector [4][16][17][18][19][20]

Group 1: ETF Performance - As of January 21, the Medical Equipment ETF (159873) saw a net subscription of 3 million units, with a turnover rate of 8.04% and a transaction volume of 18.88 million yuan [1] - The Medical Equipment ETF reached a new high with a total size of 379 million units [1] - The Medical Equipment ETF has experienced continuous net inflows over the past 10 days, totaling 119 million yuan [1] Group 2: Innovation Drug ETF Highlights - The Innovation Drug ETF Tianhong (517380) achieved a new size of 1.88 billion yuan and a total of 2.36 billion units, both marking new highs since its inception [2] - The Innovation Drug ETF has seen continuous net inflows for 12 days, accumulating 426 million yuan [3] Group 3: Market Trends and Events - A new guideline was released by the National Healthcare Security Administration on January 20, focusing on pricing for surgical robots and other medical services, establishing 37 pricing projects and 5 additional items [6] - The JPM 2026 conference highlighted the strength of Chinese innovative drugs, with significant collaborations between Chinese companies and multinational giants, indicating a shift from asset export to global participation [7] Group 4: Institutional Insights - According to Founder Securities, the implementation of the new pricing guideline will promote the clinical adoption of innovative technologies and drive demand for terminal equipment and surgical assistance [8] Group 5: Product Features - The Medical Equipment ETF (159873) has a high content of brain-computer interface stocks, accounting for over 19%, and includes nearly 80% of stocks from the Sci-Tech Innovation Board and the Growth Enterprise Market [4]